T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H1 2019
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H1 2019
SUMMARY
According to the recently published report 'T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H1 2019'; T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) pipeline Target constitutes close to 14 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - T-Cell surface glycoprotein CD3 epsilon chain also known as CD3E is a polypeptide encoded by the CD3E gene. T-cell surface glycoprotein CD3 epsilon chain interacts with TOP2B, CD3EAPand NCK2. The CD3 complex mediates signal transduction, resulting in T-cell activation and proliferation.
The report 'T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H1 2019' outlays comprehensive information on the T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 3, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Report covers products from therapy areas Oncology, Metabolic Disorders, Central Nervous System, Gastrointestinal, Genetic Disorders, Immunology and Infectious Disease which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Multiple Sclerosis, Type 1 Diabetes (Juvenile Diabetes), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Amyotrophic Lateral Sclerosis, B-Cell Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Inflammation, Crohn's Disease (Regional Enteritis), Down Syndrome, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Hepatitis B, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Lymphoblastic Lymphoma, Multiple Myeloma (Kahler Disease), Nodal Marginal Zone B-Cell Lymphoma, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Primary Biliary Cirrhosis, Primary Mediastinal B-Cell Lymphoma, Prostate Cancer, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Solid Tumor, Splenic Marginal Zone B-Cell Lymphoma, Traumatic Brain Injury, Type 2 Diabetes and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H1 2019'; T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) pipeline Target constitutes close to 14 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - T-Cell surface glycoprotein CD3 epsilon chain also known as CD3E is a polypeptide encoded by the CD3E gene. T-cell surface glycoprotein CD3 epsilon chain interacts with TOP2B, CD3EAPand NCK2. The CD3 complex mediates signal transduction, resulting in T-cell activation and proliferation.
The report 'T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H1 2019' outlays comprehensive information on the T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 3, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Report covers products from therapy areas Oncology, Metabolic Disorders, Central Nervous System, Gastrointestinal, Genetic Disorders, Immunology and Infectious Disease which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Multiple Sclerosis, Type 1 Diabetes (Juvenile Diabetes), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Amyotrophic Lateral Sclerosis, B-Cell Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Inflammation, Crohn's Disease (Regional Enteritis), Down Syndrome, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Hepatitis B, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Lymphoblastic Lymphoma, Multiple Myeloma (Kahler Disease), Nodal Marginal Zone B-Cell Lymphoma, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Primary Biliary Cirrhosis, Primary Mediastinal B-Cell Lymphoma, Prostate Cancer, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Solid Tumor, Splenic Marginal Zone B-Cell Lymphoma, Traumatic Brain Injury, Type 2 Diabetes and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)
- The report reviews T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics and enlists all their major and minor projects
- The report assesses T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Overview
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Companies Involved in Therapeutics Development
Amgen Inc
Avacta Life Sciences Ltd
Celgene Corp
F. Hoffmann-La Roche Ltd
Numab Innovation AG
Provention Bio Inc
SYNIMMUNE GmbH
Tiziana Life Sciences Plc
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Drug Profiles
AMG-330 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVA-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibodies to Target CD3, CD16 and HBsAg for HBV Infection and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Target CD3E and PSMA for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
blinatumomab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EM-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
foralumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to target CD3E and Cells Expressing NKG2D for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
otelixizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pasotuxizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-7082859 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TACSYN - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teplizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Dormant Products
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Product Development Milestones
Featured News & Press Releases
Apr 09, 2019: Provention Bio Initiates Phase 3 PROTECT clinical trial with PRV-031 (Teplizumab) in patients with recent onset Type 1 Diabetes
Mar 20, 2019: Tiziana submits IND application for oral formulation of Foralumab for treatment of NASH
Mar 06, 2019: Blinatumomab for acute lymphoblastic leukaemia for people with minimal residual disease activity in remission
Jan 23, 2019: Amgen’s Blincyto gets expanded indication for B-cell ALL in Europe
Dec 03, 2018: Amgen announces first-in-human data evaluating investigational novel BiTE Immunotherapy AMG 330 At ASH 2018
Nov 28, 2018: Tiziana announces initiation of phase 1 clinical trial with nasal administration of Foralumab, a fully human anti-cluster definition 3 monoclonal antibody (anti-CD3 mAb), in healthy volunteers
Nov 27, 2018: BLINCYTO for drip infusion 35 µg launched in Japan for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia
Nov 16, 2018: Amgen receives CHMP positive opinion to expand use Of BLINCYTO (Blinatumomab) in patients with minimal residual disease-positive B-Cell precursor Acute Lymphoblastic Leukemia
Nov 01, 2018: Roche presents early data for novel T-cell engaging bispecific antibody CD20-TCB at the American Society of Hematology 2018 Annual Meeting
Nov 01, 2018: Amgen to present new data on Blinatumomab at ASH 2018
Nov 01, 2018: Amgen to present new data on its acute myeloid leukemia drug candidate AMG 330 at ASH 2018
Sep 24, 2018: U.S. Food and Drug Administration approves application for Investigational New Drug; Phase I clinical study set to commence enrolment in late 2018
Sep 24, 2018: BLINCYTO (blinatumomab) approved in japan for the treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Aug 29, 2018: European Commission approves BLINCYTO (blinatumomab) for use in pediatric patients with philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia
Aug 16, 2018: Tiziana Life Sciences: filing of investigational new drug application
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Overview
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Companies Involved in Therapeutics Development
Amgen Inc
Avacta Life Sciences Ltd
Celgene Corp
F. Hoffmann-La Roche Ltd
Numab Innovation AG
Provention Bio Inc
SYNIMMUNE GmbH
Tiziana Life Sciences Plc
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Drug Profiles
AMG-330 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVA-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibodies to Target CD3, CD16 and HBsAg for HBV Infection and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Target CD3E and PSMA for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
blinatumomab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EM-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
foralumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to target CD3E and Cells Expressing NKG2D for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
otelixizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pasotuxizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-7082859 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TACSYN - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teplizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Dormant Products
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Product Development Milestones
Featured News & Press Releases
Apr 09, 2019: Provention Bio Initiates Phase 3 PROTECT clinical trial with PRV-031 (Teplizumab) in patients with recent onset Type 1 Diabetes
Mar 20, 2019: Tiziana submits IND application for oral formulation of Foralumab for treatment of NASH
Mar 06, 2019: Blinatumomab for acute lymphoblastic leukaemia for people with minimal residual disease activity in remission
Jan 23, 2019: Amgen’s Blincyto gets expanded indication for B-cell ALL in Europe
Dec 03, 2018: Amgen announces first-in-human data evaluating investigational novel BiTE Immunotherapy AMG 330 At ASH 2018
Nov 28, 2018: Tiziana announces initiation of phase 1 clinical trial with nasal administration of Foralumab, a fully human anti-cluster definition 3 monoclonal antibody (anti-CD3 mAb), in healthy volunteers
Nov 27, 2018: BLINCYTO for drip infusion 35 µg launched in Japan for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia
Nov 16, 2018: Amgen receives CHMP positive opinion to expand use Of BLINCYTO (Blinatumomab) in patients with minimal residual disease-positive B-Cell precursor Acute Lymphoblastic Leukemia
Nov 01, 2018: Roche presents early data for novel T-cell engaging bispecific antibody CD20-TCB at the American Society of Hematology 2018 Annual Meeting
Nov 01, 2018: Amgen to present new data on Blinatumomab at ASH 2018
Nov 01, 2018: Amgen to present new data on its acute myeloid leukemia drug candidate AMG 330 at ASH 2018
Sep 24, 2018: U.S. Food and Drug Administration approves application for Investigational New Drug; Phase I clinical study set to commence enrolment in late 2018
Sep 24, 2018: BLINCYTO (blinatumomab) approved in japan for the treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Aug 29, 2018: European Commission approves BLINCYTO (blinatumomab) for use in pediatric patients with philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia
Aug 16, 2018: Tiziana Life Sciences: filing of investigational new drug application
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Amgen Inc, H1 2019
Pipeline by Avacta Life Sciences Ltd, H1 2019
Pipeline by Celgene Corp, H1 2019
Pipeline by F. Hoffmann-La Roche Ltd, H1 2019
Pipeline by Numab Innovation AG, H1 2019
Pipeline by Provention Bio Inc, H1 2019
Pipeline by SYNIMMUNE GmbH, H1 2019
Pipeline by Tiziana Life Sciences Plc, H1 2019
Dormant Projects, H1 2019
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Amgen Inc, H1 2019
Pipeline by Avacta Life Sciences Ltd, H1 2019
Pipeline by Celgene Corp, H1 2019
Pipeline by F. Hoffmann-La Roche Ltd, H1 2019
Pipeline by Numab Innovation AG, H1 2019
Pipeline by Provention Bio Inc, H1 2019
Pipeline by SYNIMMUNE GmbH, H1 2019
Pipeline by Tiziana Life Sciences Plc, H1 2019
Dormant Projects, H1 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019
COMPANIES MENTIONED
Amgen Inc
Avacta Life Sciences Ltd
Celgene Corp
F. Hoffmann-La Roche Ltd
Numab Innovation AG
Provention Bio Inc
SYNIMMUNE GmbH
Tiziana Life Sciences Plc
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019
COMPANIES MENTIONED
Amgen Inc
Avacta Life Sciences Ltd
Celgene Corp
F. Hoffmann-La Roche Ltd
Numab Innovation AG
Provention Bio Inc
SYNIMMUNE GmbH
Tiziana Life Sciences Plc
